Cancer Vaccines

Idera Pharmaceuticals Announces Hart-Scott-Rodino Clearance for Collaboration Agreement with Merck KGaA

Published in Lab Law Weekly, February 22nd, 2008

Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) announced that it received clearance under the Hart-Scott-Rodino Antitrust Improvements Act for its worldwide licensing and collaboration agreement with Merck KGaA of Darmstadt, Germany, announced in December 2007. With the grant of HSR clearance, the agreement is now in effect and Idera is entitled to receive an upfront licensing fee of $40 million from Merck KGaA.

Under the agreement, Idera exclusively licensed the therapeutic oncology applications, excluding cancer vaccines, of its lead TLR9 agonists, IMO-2055 and IMO-2125. In addition, using Idera's chemistry-based approach to the design and creation of TLR-targeted...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Law Weekly

Source: Lab Law Weekly (2008-02-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry